ATE480232T1 - Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden - Google Patents

Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden

Info

Publication number
ATE480232T1
ATE480232T1 AT03732288T AT03732288T ATE480232T1 AT E480232 T1 ATE480232 T1 AT E480232T1 AT 03732288 T AT03732288 T AT 03732288T AT 03732288 T AT03732288 T AT 03732288T AT E480232 T1 ATE480232 T1 AT E480232T1
Authority
AT
Austria
Prior art keywords
helicobacter pylori
pleuromutilines
diseases caused
treat diseases
pleuromutilin
Prior art date
Application number
AT03732288T
Other languages
English (en)
Inventor
Gerd Ascher
Johannes Hildebrandt
Original Assignee
Nabriva Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabriva Therapeutics Ag filed Critical Nabriva Therapeutics Ag
Application granted granted Critical
Publication of ATE480232T1 publication Critical patent/ATE480232T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03732288T 2002-04-23 2003-04-22 Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden ATE480232T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0209262.5A GB0209262D0 (en) 2002-04-23 2002-04-23 Organic compounds
PCT/EP2003/004173 WO2003090740A1 (en) 2002-04-23 2003-04-22 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori

Publications (1)

Publication Number Publication Date
ATE480232T1 true ATE480232T1 (de) 2010-09-15

Family

ID=9935350

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03732288T ATE480232T1 (de) 2002-04-23 2003-04-22 Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden

Country Status (11)

Country Link
US (1) US7790749B2 (de)
EP (1) EP1501495B1 (de)
JP (1) JP2005529131A (de)
AT (1) ATE480232T1 (de)
AU (1) AU2003239813A1 (de)
DE (1) DE60334094D1 (de)
ES (1) ES2354972T3 (de)
GB (1) GB0209262D0 (de)
SI (1) SI1501495T1 (de)
TW (1) TW200306294A (de)
WO (1) WO2003090740A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
WO2007000004A1 (en) * 2005-06-27 2007-01-04 Nabriva Therapeutics Forschungs Gmbh Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GB0515995D0 (en) * 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
EP1808431A1 (de) * 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Mutilin Derivate und ihre Verwendung als Arzneimittel
EP1972618A1 (de) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin-Derivate zur Behandlung von Krankheiten vermittelt durch Mikroben
EP2014645A1 (de) * 2007-07-13 2009-01-14 Nabriva Therapeutics AG Pleuromutilin-derivate und ihre Verwendung als antimikrobielles Wirkungsmittel
EP2159220A1 (de) 2008-09-02 2010-03-03 Nabriva Therapeutics AG Organische Verbindungen
CN102924350B (zh) * 2012-10-31 2014-04-09 中国农业科学院兰州畜牧与兽药研究所 截短侧耳素衍生物及其制备方法和应用
CN103265442B (zh) * 2013-06-05 2017-02-08 北京理工大学 一类新型截短侧耳素衍生物及其制备方法和抗肿瘤用途
HRP20210010T1 (hr) 2015-06-17 2021-03-05 Nabriva Therapeutics GmbH Injekcijske farmaceutske formulacije lefamulina
TWI762573B (zh) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化
CN116687904B (zh) * 2023-03-28 2025-05-06 中国药科大学 截短侧耳素抗生素在制备抗肿瘤及逆转分子靶向治疗耐药的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3560511D1 (en) 1984-02-17 1987-10-01 Sandoz Ag Pleuromutilin derivatives, process for their preparation and their use
CA2042138A1 (en) 1990-04-18 1992-11-09 Hiroo Abe Agents for preventing or treating bacterial diseases of fishes
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
WO2001074788A1 (en) * 2000-04-04 2001-10-11 Smithkline Beecham Plc 2-hydroxy-mutilin carbamate derivatives for antibacterial use
DE10030781A1 (de) 2000-06-29 2002-01-17 Hassan Jomaa Kombinationspräparate von 3-N-Formylhydroxylaminopropylphosphonsäurederivaten oder 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten mit spezielen pharmazeutischen Wirkstoffen
GB0017031D0 (en) * 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
PE20020676A1 (es) 2000-09-13 2002-08-27 Biochemie Gmbh Compuestos de mutilina como antibacterianos
GB0024811D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
AU2003239813A1 (en) 2003-11-10
HK1073250A1 (en) 2005-09-30
JP2005529131A (ja) 2005-09-29
US7790749B2 (en) 2010-09-07
WO2003090740A1 (en) 2003-11-06
GB0209262D0 (en) 2002-06-05
EP1501495A1 (de) 2005-02-02
SI1501495T1 (sl) 2011-01-31
US20050131023A1 (en) 2005-06-16
EP1501495B1 (de) 2010-09-08
DE60334094D1 (de) 2010-10-21
TW200306294A (en) 2003-11-16
ES2354972T3 (es) 2011-03-21

Similar Documents

Publication Publication Date Title
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
CY1107484T1 (el) Παραγωγα γκελνταναμυκινης χρησιμοποιουμενα για τη θεραπεια καρκινου
MY169308A (en) Treatment of tnf? related disorders
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
ATE480232T1 (de) Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
ZA200407216B (en) Tuberculosis treatment.
NO20045056L (no) Fremgangsmater for behandling av hepatitt
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE404202T1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE602004011051D1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
PL371205A1 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
DE60305068D1 (de) Behandlung von mastalgie mit4-hydroxy-tamoxifen
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
ATE304861T1 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
ATE486612T1 (de) Verfahren zur behandlung von diabetes typ 2
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
DE60224064D1 (de) Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties